DUBAI, UAE, 8 February 2024 – MGI Tech, a company committed to building core tools and technology to lead life science, today announced partnership with Dante Labs, a leading global genomics and precision medicine company. Unveiled at MEDLAB Middle East 2024 exhibition, the collaboration is set to increase access to advanced genomic technologies throughout the Middle East region.

Roy Tan, General Manager of MGI Asia Pacific, expressed his enthusiasm during the announcement, "Partnering with Dante Labs underscores our unwavering dedication to make innovative genomic technologies available globally. We are excited to quicken the pace at which these advancements become accessible in the Middle East."

Dante Genomics is a leading global genomics and precision medicine company. The company's mission, “To leverage whole genome sequencing technology and variant interpretation, so that you can make informed decisions about your health and your future”, aligns seamlessly with MGI's vision. This shared commitment forms the cornerstone of the collaboration between the two companies.

Under the partnership, MGI and Dante Labs will establish a joint demo lab and customer experience center in the Middle East. This center will provide local researchers and users with unique access to MGI's cutting-edge technology portfolio, including single cell, spatial omics, DNBSEQ platforms, laboratory automation systems, and bioinformatics products.

The collaboration will mainly focus on the creation of a customer experience center. Moreover, harnessing the power of MGI’s advanced sequencing technologies, the alliance plans to collaborate on the development and validation of whole genome and whole exome sequencing using the DNBSEQ-T7* platform, ensuring the highest standards in genomic analysis. Equipped with MGI’s automation and reagents, a regional network of sample collection centers is to be established to further expand Dante Lab’s service availability and regional coverage.

“Teaming up with MGI, our aim is to deliver superior, affordable, and flexible healthcare solutions to the Middle East, GCC, and North Africa, with the UAE as the central hub for excellence," remarked Generoso Ianniciello, Vice President of Dante Labs. "MGI‘s formidable sequencing technologies will significantly contribute to our offering, creating a strategic win-win for both organizations and extending our market presence in the region."

The partnership between MGI and Dante Labs underscores the two companies' shared vision of providing improved healthcare solutions through the adoption of genomics, striving to make advanced technology accessible, beneficial, and locally secure for all. Together, the MGI and Dante Genomics are committed to delivering on multiomics data-driven decisions for precision health, emphasizing our dedication to advancing healthcare innovation.

"We continue to enhance our vision by positioning the UAE as the premier center for Research and Diagnostics Excellence in the region, reinforcing our commitment to providing cutting-edge healthcare solutions with localized data security and safety to the UAE, Middle East, GCC, Africa and Asia," said Andrea Riposati, CEO and Co-Founder of Dante Genomics.

About MGI Tech

MGI Tech Co. Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers*, and its multi-omics platforms include genetic sequencing*, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.

* For Research Use Only. Not for use in diagnostic procedures.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing. For more information, please visit https://dantegenomics.com/ .